Related Experiment Videos
Interleukin-6 potentiates neutrophil priming with platelet-activating factor
W L Biffl1, E E Moore, F A Moore
1Department of Surgery, Denver General Hospital, University of Colorado Health Sciences Center.
Archives of Surgery (Chicago, Ill. : 1960)
|November 1, 1994
Summary
Interleukin-6 (IL-6) and platelet-activating factor (PAF) work together to prime polymorphonuclear neutrophils (PMNs). This synergistic action of IL-6 and PAF in PMN priming may explain IL-6
Area of Science:
- Immunology
- Cellular Biology
- Inflammation Research
Background:
- Polymorphonuclear neutrophil (PMN) priming is crucial in hyperinflammatory conditions like ARDS and multiple organ failure.
- Elevated Interleukin-6 (IL-6) levels correlate with poor outcomes in trauma, burns, and surgery.
- Previous research indicated IL-6 might prime PMNs for heightened cytotoxicity, but direct priming for superoxide release was not observed.
Purpose of the Study:
- To investigate if IL-6 primes PMNs, particularly in combination with platelet-activating factor (PAF).
Main Methods:
- Human PMNs were incubated with varying concentrations and durations of IL-6, PAF, or both.
- Superoxide production was measured after stimulation with formyl-methionyl-leucyl-phenylalanine (fMLP).
Main Results:
- IL-6 alone did not prime PMNs for superoxide release.
- PAF demonstrated dose- and time-dependent priming of PMNs.
- A combination of IL-6 (10 ng/mL) and a low concentration of PAF (0.1 ng/mL) synergistically primed PMNs.
Conclusions:
- IL-6 and PAF exhibit synergistic activity in priming PMNs in vitro.
- This synergy provides insight into the role of IL-6 in pathological inflammatory conditions.